Fact Check: Misguided Attacks on Follow-On Patents Would Harm Patients
Critics of the U.S. patent system are increasingly targeting follow-on innovation in the biopharmaceutical sector. In an effort to weaken follow-on patents — or those issued after a product has already been introduced — they claim that these innovations are trivial, extend exclusivity unfairly, and drive up drug costs. But as a new report from